Aczone Generic Approval In Sight, All Clear At Sites Key To Torrent’s US Outlook
Molnupiravir Launched In India
Executive Summary
Torrent expects US FDA’s final approval for Allergan/Almirall’s Aczone, a dapsone formulation for acne vulgaris, in February, even as it awaits regulatory clearance for manufacturing sites. Meanwhile, it has launched molnupiravir in India and is hiking its domestic sales force by 400-500.
You may also be interested in...
Coronavirus Update: Generics And Hurdles For Molnupiravir, More Japan Approvals
More generic deals but also US approval hurdles for Merck's oral antiviral, while Japan approves more options and Valneva's vaccine candidate shows promise against Omicron.
Wave Of Molnupiravir Generics In India Amid Early Physician Cheer
India authorizes molnupiravir for restricted emergency use in COVID-19, marking the arrival of around a dozen “affordable” generics of Merck & Co. and Ridgeback Biotherapeutics' oral antiviral. Physicians say data are “pretty compelling” notwithstanding the narrow FDA nod.
Torrent Settles With BMS For Revlimid, Launch Timeline Undisclosed
Torrent has reached a settlement with BMS’ Celgene over oncology blockbuster Revlimid, officials said during a Q2 call, but declined to disclose launch timelines for the generic. Meanwhile, the Indian company continues to evaluate an option to enter the injectables segment in the US as revenues slide.